Scholarlink

Purpose of Review <p>This review aims to provide a comprehensive update to healthcare providers on the assessment and subsequent management of low-flow aortic stenosis.</p> Recent Findings <p>An aging population with a greater burden of cardiovascular risk factors has contributed to an increasing prevalence of aortic stenosis. The classification of the discordant low-flow cohort of aortic stenosis remains difficult and sub-optimal in the face of a heterogeneous disease population. Recent research has investigated use of echocardiographic flow parameters to categorise and prognosticate the low-flow aortic stenosis cohort. There is an increased awareness of the overlap between cardiac amyloidosis and the low-flow aortic stenosis group which has treatment implications. TAVI holds promise as a safer alternative to SAVR in this multimorbid, high-risk patient cohort.</p> Summary <p>Assessment and management of the low-flow aortic stenosis group needs to be highly individualised according to phenotype and comorbidities. This is best managed within the multidisciplinary Heart Team approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low-flow Low-gradient Aortic Stenosis: Foundations, Challenges, and Solutions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月13日

查看全文
  • Lachlan Weir,
  • Thomas Meredith,
  • Christopher Hayward,
  • David Muller,
  • Michael Feneley,
  • Mayooran Namasivayam

摘要

Purpose of Review

This review aims to provide a comprehensive update to healthcare providers on the assessment and subsequent management of low-flow aortic stenosis.

Recent Findings

An aging population with a greater burden of cardiovascular risk factors has contributed to an increasing prevalence of aortic stenosis. The classification of the discordant low-flow cohort of aortic stenosis remains difficult and sub-optimal in the face of a heterogeneous disease population. Recent research has investigated use of echocardiographic flow parameters to categorise and prognosticate the low-flow aortic stenosis cohort. There is an increased awareness of the overlap between cardiac amyloidosis and the low-flow aortic stenosis group which has treatment implications. TAVI holds promise as a safer alternative to SAVR in this multimorbid, high-risk patient cohort.

Summary

Assessment and management of the low-flow aortic stenosis group needs to be highly individualised according to phenotype and comorbidities. This is best managed within the multidisciplinary Heart Team approach.